Nephro Care India Limited (“NCIL” or “The Company”), a leading multi-speciality healthcare provider in East India, announced the filing of its Draft Red Herring Prospectus (DRHP) with NSE Emerge. The company’s initial public offering comprises a fresh issuance of 45,84,000 Equity Shares, each with a face value of Rs. 10. Nephro Care files DRHP

    Corporate Capital Ventures Private Limited is the sole Book Running Lead Manager to the Issue, and Bigshare Services Private Limited is the Registrar. Corporate Capital Ventures has completed a string of successful SME IPOs in the recent months, including Trust Fintech, Creative Graphics, Alpex Solar, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.

    In December 2023, Nephro Care India Limited successfully closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC Ltd, Deepak Parekh, chairman of HDFC Securities Bharat Shah, and Rajendra Agarwal, Founder and MD of Macleods Pharmaceuticals, among others.

    The Kolkata-headquartered healthcare provider offers a wide range of clinical and lifestyle solutions and renal insufficiency treatment to patients. The treatment framework at NCIL covers the entire range of lifestyle, physiological and spiritual aspects of wellness.

    NCIL currently provides healthcare services to around 900 chronic kidney disease (CKD) patients every month. It engages over 5 permanent doctors along with 10 visiting consultants led by 70 experienced professionals at its flagship Salt Lake clinic, which is spread over 5,352 sq. ft., and two satellite clinics at Salt Lake (HB 113) and Chandannagar, near Kolkata. The company is also in the process of opening three more satellite clinics at Alipurduar and Shyambazar in West Bengal and Balasore in Odisha.



    Nephro Care files DRHP

    Leave a Reply

    Your email address will not be published. Required fields are marked *